Current Report Filing (8-k)
06 Outubro 2021 - 5:16PM
Edgar (US Regulatory)
0000724445
false
NONE
0000724445
2021-10-06
2021-10-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
October 6, 2021
Date of Report (Date of earliest event reported)
Burzynski Research Institute, Inc.
(Exact name of registrant as specified in its
charter)
|
Delaware
|
|
000-23425
|
|
76-0136810
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
9432 Katy Freeway, Suite 200, Houston,
TX 77055
(Address of principal executive offices)
(713) 335-5697
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
None
|
|
BZYR
|
|
None
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On October 6, 2021, the board of directors
(the “Board”) of Burzynski Research Institute, Inc. (the “Company”) appointed Monika Szopa-Paszkowiak to
the Board, to fill a vacancy as a result of the passing away of Dr. Barbara Burzynski, effective as of the same date, to serve until
her successor is duly appointed and qualified, or her earlier death, resignation or removal. Ms. Szopa-Paszkowiak is currently a
real estate agent with Coldwell Banker and also assists with her husband’s medical practice in Oklahoma. Prior to her current occupations,
Ms. Szopa-Paszkowiak assisted the Company with pharmaceutical manufacturing and procurement of active ingredients and equipment necessary
for the manufacture of Antineoplaston formulations. She had also worked with patients and directed the Human Resources Department at Burzynski
Clinic. Ms. Szopa-Paszkowiak holds a bachelor degree from Houston Baptist University. She is the step-daughter of Dr. Stanislaw
R. Burzynski, who currently serves as the President and Chairman of the Company. Ms. Szopa-Paszkowiak is expected to be a valuable
member of the Board.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
Date: October 6, 2021
|
BURZYNSKI RESEARCH INSTITUTE, INC.
|
|
|
|
|
|
|
By:
|
/s/ Stanislaw R. Burzynski
|
|
|
|
Stanislaw R. Burzynski
|
|
|
|
President and Chairman of the Board of Directors
|
Burzynski Research Insti... (PK) (USOTC:BZYR)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Burzynski Research Insti... (PK) (USOTC:BZYR)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
